Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML)

被引:0
|
作者
Al-Kali, Aref [1 ]
Jones, Dan [1 ]
Cortes, Jorge [1 ]
Faderl, Stefan [1 ]
Ao, Xue [1 ]
Garcia-Manero, Guillermo [1 ]
Borthakur, Gautam [1 ]
Konopleva, Marina [1 ]
Brandt, Mark [1 ]
Andreeff, Michael [1 ]
Kantarjian, Hagop [1 ]
Ravandi, Farhad [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:820 / 821
页数:2
相关论文
共 50 条
  • [21] Low Relapse Rate in Younger Patients ≤ 60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy
    Wang, Eunice S.
    Tallman, Martin S.
    Stone, Richard M.
    Walter, Roland B.
    Karanes, Chatchada
    Jain, Vinay
    Collins, Robert H.
    BLOOD, 2017, 130
  • [22] Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)
    Wang, Eunice S.
    Stone, Richard M.
    Tallman, Martin S.
    Walter, Roland B.
    Eckardt, John R.
    Collins, Robert
    BLOOD, 2016, 128 (22)
  • [23] Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia
    Fathi, Amir T.
    Lin, William M.
    Durazzo, Tyler
    Piris, Adriano
    Sadrzadeh, Hossein
    Bernardo, Lindsay
    Borger, Darrel R.
    McAfee, Steven L.
    Kroshinsky, Daniela
    Chen, Yi-Bin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) : E70 - E72
  • [24] Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
    Nazha, Aziz
    Kantarjian, Hagop
    Ravandi, Farhad
    Huang, Xuelin
    Choi, Sangbum
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Konopleva, Marina
    Cortes, Jorge
    Ferrajoli, Alessandra
    Kornblau, Steve
    Daver, Naval
    Pemmaraju, Naveen
    Andreeff, Michael
    Estrov, Zeev
    Du, Min
    Brandt, Mark
    Faderl, Stefan
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (11) : 961 - 966
  • [25] A Randomized Phase 2 Study of Idarubicin and Cytarabine With Clofarabine or Fludarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
    Jabbour, Elias
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Xiao, Lianchun
    Garcia-Manero, Guillermo
    Plunkett, William
    Gandhi, Varsha
    Sasaki, Koji
    Pemmaraju, Naveen
    Daver, Naval G.
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Estrov, Zeev
    Kadia, Tapan M.
    Wierda, William G.
    DiNardo, Courtney D.
    Brandt, Mark
    O'Brien, Susan M.
    Cortes, Jorge E.
    Kantarjian, Hagop
    CANCER, 2017, 123 (22) : 4430 - 4439
  • [26] Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)
    Nazha, Aziz
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Huang Xuelin
    Choi, Sangbum
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautarn
    Kadia, Tapan M.
    Konopleva, Marina
    Cortes, Jorge E.
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Andreeff, Michael
    Du, Min
    Brandt, Mark
    Faderl, Stefan H.
    BLOOD, 2013, 122 (21)
  • [27] Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML).
    Mathisen, Michael
    Kantarjian, Hagop
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan M.
    Daver, Naval Guastad
    O'Brien, Susan Mary
    Dorkhom, Stephan Joseph
    Pierce, Sherry
    Lira, Cynthia
    Cortes, Jorge E.
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)
    Abuasab, Tareq
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Alvarado, Yesid
    Yilmaz, Musa
    Pemmaraju, Naveen
    Chien, Kelly S.
    Mohamed, Shehab Fareed
    Daver, Naval
    Kornblau, Steven M.
    Burger, Jan A.
    Jain, Nitin
    Islam, Rubiul
    DiNardo, Courtney D.
    Borthakur, Gautam
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [29] Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients (pts) with FLT3 mutated acute myeloid leukemia (AML).
    Abuasab, Tareq
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Bravo, Guillermo Montalban
    Valero, Yesid Alvarado
    Daver, Naval Guastad
    Yilmaz, Musa
    Pemmaraju, Naveen
    Chien, Kelly Sharon
    Kornblau, Steven Mitchell
    Burger, Jan Andreas
    Jain, Nitin
    Islam, Rabiul
    Dinardo, Courtney Denton
    Borthakur, Gautam
    Jabbour, Elias
    Ravandi, Farhad
    Kadia, Tapan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)
    Wang, Eunice S.
    Griffiths, Elizabeth A.
    Walter, Roland B.
    Tallman, Martin S.
    Goldberg, Aaron D.
    Messahel, Boo
    Stone, Richard M.
    BLOOD, 2019, 134